Yuliya I. Zhilenkova

Yuliya I. Zhilenkova

Auto-generated profile, based on publicly available information

Yuliya I. Zhilenkova

Almazov National Medical Research Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2023 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
АКАндрей Александрович Карпов
Андрей Александрович Карпов
МСМария Александровна Симакова
Мария Александровна Симакова
Pavel DocshinPavel Docshin
Pavel Docshin
YZYuliya I. Zhilenkova
Yuliya I. Zhilenkova
LSLeonid Shilenko
Leonid Shilenko
OMOlga Moiseeva
Olga Moiseeva
HighlightsIL-8 and MCP-1 have a significant role in the CTEPH pathogenesis, which indicates the importance of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, cardiac structural changes and plasma biochemical parameters were determined. AbstractBackground. Chronic thromboembolic pulmonary hypertension (CTEPH) pathogenesis is complex and not fully understood. Particular attention to the microvascular damage genesis in CTEPH is given to aseptic inflammation, which in turn could be mediated through various molecular mechanisms. According to the conflicting and incomplete data on changes in the profile of factors controlling inflammation in CTEPH, research in this field would identify new therapeutic targets for the prevention and treatment of CTEPH.Aim. To study the profile of plasma proinflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and evaluate the coupling of these cytokines with the main morphofunctional and laboratory values of the disease severity.Methods. 34 patients with CTEPH were included in this study. To characterize the group, the following methods were used: echocardiographic examination, catheterization of the right cardiac chambers. Biomarkers of heart failure, systemic inflammation, as well as erythropoiesis and iron metabolism were assessed in all patients. The control group included 10 donors. To study the proinflammatory cytokine profile in plasma, interleukins (IL) 6, 8, 18, monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase 9 were determined using standard enzyme-linked immunosorbent assay (ELISA) kits.Results. Hemodynamic and morphofunctional changes in the pulmonary circulation specific to pulmonary hypertension were determined with catheterization of the right cardiac chambers and echocardiography. During plasma proinflammatory cytokines analysis, a significant increase in the level of IL-8 (p = 0.030) and MCP-1 (p = 0.031) in CTEPH group compared to the control group was observed. No significant differences for other analyzed markers were found. In the elaboration of the correlation analysis, moderate inverse coupling between proinflammatory markers and hemodynamic parameters characterizing the CTEPH severity were revealed, as well as positive correlations with parameters of remodeling of the right cardiac chambers and iron metabolism.Conclusion. The increased levels of IL-8 and MCP-1 in patients with CTEPH identified in the present study indicate a significant role of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, structural cardiac changes and plasma biochemical parameters were determined. Based on the obtained data, it is possible to develop new medicinal substances, targeting towards proinflammatory cytokines, their receptors and signaling pathways.

15 March 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
TVT. V. Vavilova
T. V. Vavilova
OSOlga Sirotkina
Olga Sirotkina
NCN. Yu. Chernysh
N. Yu. Chernysh
VBV. S. Berestovskaya
V. S. Berestovskaya
YZYu. I. Zhilenkova
Yu. I. Zhilenkova
EPE. V. Parmon
E. V. Parmon
At the end of the last century and, especially, in the first two decades of the 21st century, a significant technological breakthrough took place in clinical laboratory diagnostics in Russia. The transition from manual techniques to high-tech and high-performance automated systems has changed the potential of laboratory medicine. The laboratory has become a high-tech, rapidly developing branch of medical organizations. Following the changes in technology, the range of diagnostic tests began to alter, while the list of laboratory tests available grew. These dynamics are growing every year. Simple routine techniques, practiced for all patients, are complemented by more specific tests. The place of conventional routine tests has been determined by many years of practical experience, while modern analyzers allow the use of tests with a high evidence value of recommendations, which, in the context of evidence-based medicine, enable the clinician to conduct a personalized diagnostic search. At the same time, in order to use all the possibilities of laboratory medicine, the discipline Clinical Laboratory Diagnostics should be included in educational programs at different stages of a doctor's training.

20 November 2023 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
MOMelnichnikova Olga
Melnichnikova Olga
ZYZhilenkova Yuliya
Zhilenkova Yuliya
Vitaliy Leonidovich LukinovVitaliy Leonidovich Lukinov
Vitaliy Leonidovich Lukinov
ZEZolotova Ekaterina
Zolotova Ekaterina
PKPishchulov Konstantin
Pishchulov Konstantin
VTVavilova Tatyana
Vavilova Tatyana

1 January 2021 in Laboratory Service
Verified
Journal Article
Closed access
TVT.V. Vavilova
T.V. Vavilova
OSOlga Sirotkina
Olga Sirotkina
AEA.I. Ermakov
A.I. Ermakov
YZYu.I. Zhilenkova
Yu.I. Zhilenkova
LGL.B. Gaikovaya
L.B. Gaikovaya
Одним из молекулярных механизмов активации свертывания при COVID-19 являются процессы микровезикуляции клеток. Выраженность этих процессов в зависимости от степени тяжести течения заболевания и связь с клиническими проявлениями тромбозов остается недостаточно понятной. ЦЕЛЬ ИССЛЕДОВАНИЯ Определение характера и количества микровезикул клеток крови и эндотелия у больных с COVID-19 среднетяжелого течения, госпитализированных в стационар. МАТЕРИАЛ И МЕТОДЫ В исследование были включены 43 пациента, госпитализированных в связи со среднетяжелым течением COVID-19 и поражением легких 2-й степени, и 14 лиц контрольной группы без признаков острой респираторной инфекции и факторов риска тромбозов. РЕЗУЛЬТАТЫ Выявлено увеличение количества микровезикул тромбоцитарного, лейкоцитарного и эритроцитарного происхождения (кроме эндотелиальных, которые продемонстрировали снижение по сравнению с контролем) в отсутствие у большинства пациентов повышения уровня D-димера. Отмечена положительная динамика за период госпитализации на фоне этиопатогенетической терапии без нормализации количества тромбоцитарных микровезикул. ВЫВОДЫ Высокая активность формирования клеточных микровезикул у пациентов со среднетяжелым течением COVID-19 отражает потенциальный риск тромбоэмболических осложнений даже в условиях отсутствия повышения уровня D-димера. Процесс микровезикуляции коррелирует со степенью тяжести воспалительной реакции. Этиопатогенетическое лечение с включением в протокол антикоагулянтной терапии позволяет снизить продукцию микровезикул, но не нормализует процесс полностью.

26 July 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
EZE. A. Zolotova
E. A. Zolotova
YZYu. I. Zhilenkova
Yu. I. Zhilenkova
OMO. S. Melnichnikova
O. S. Melnichnikova
AKAndrei Karpov
Andrei Karpov
OMOlga Moiseeva
Olga Moiseeva
Background. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease with a poor prognosis. The role of monocytic-macrophage inflammation in the incomplete recanalization of acute thromboembolic pulmonary artery disease and the formation of CTEPH was shown. The role of the coagulo-fibrinolytic system in the pathogenesis of CTEPH remains controversial.Objective. To assess the activity of the coagulo-fibrinolytic system and its relationship with the level of monocytic chemotactic factor 1 (MCP-1), as well as the severity of the disease in patients with long-term CTEPH.Design and methods. The study included 44 patients diagnosed with CTEPH: 21 men (mean age 57,0 ± 11,9 years) and 23 women (mean age 53,8 ± 14,7 years). The diagnosis of CTEPH was verified according to the clinical guidelines of the Ministry of Health of the Russian Federation for the diagnosis and management of patients with pulmonary hypertension from 2020. The control group consisted of healthy donors (n = 19, mean age 51,0 ± 11,9 years, 10 men, 9 women). All patients were on anticoagulant therapy with enoxaparin sodium at a therapeutic dose of 1 mg/kg subcutaneously twice a day. The study of markers of the fibrinolysis and inflammation system was carried out by enzyme immunoassay: thrombin-activated fibrinolysis inhibitor (TAFI), tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), monocytic chemotactic factor 1 (MCP-1).Results. In the CTEPH group, an increase in the level of t-PA was demonstrated — 6,06 [4,502; 8,03] vs 2,95 [2,75; 3,56] ng/ml in donors (p = 0,00001). The levels of PAI-1 and TAFI did not differ in patients (34,40 [22,47; 46,43] and 94,67 [90,03; 102,80] ng/mL, respectively) and donors (24,93 [21,41; 43,88] and 92,68 [87,99; 98,29] ng/ml, respectively) (p = 0,0970 and p = 0,233). A significant increase in the level of MCP-1 was found in patients with CTEPH compared to donors (34,95 [31,00; 42,08] vs 26,05 [20,40; 31,33] pg/ml, p = 0,016, respectively). A correlation was noted between MCP-1 and fibrinolysis indices t-PA (0,402, p = 0,046), PAI-1 (0,437, p = 0,029). Correlations of MCP-1 and fibrinolysis markers with hemodynamic and physical performance indicators are also shown: MCP-1 and SvO2 (–0,574, p = 0,002), MCP-1 and cardiac index (CI) (–0,614, p = 0,001), distance in the six-minute walk test (6MWT) and t-PA (–0,435, p = 0,006).Conclusions. As a result of the study, the relationship between MCP-1 and the activity of the coagulo-fibrinolytic system and the severity of CTEPH was demonstrated. The data obtained can be used to further study the pathogenesis of postthromboembolic syndrome and develop criteria for assessing prognosis in patients with CTEPH.

22 February 2024 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
TVT.V. Vavilova
T.V. Vavilova
VSV.A. Samokhovets
V.A. Samokhovets
YZYu.I. Zhilenkova
Yu.I. Zhilenkova
The prevalence of latent iron deficiency (ID) and iron deficiency anaemia (IDA) indicates that these conditions are an important problem in modern healthcare. Early identification of IDA and its correction is particularly important for women of reproductive age. Objective. To determine the clinical effectiveness and pharmacological possibilities of iron deficiency correction in women of reproductive age with iron deficiency anaemia. Material and methods. A prospective monitoring of patients with IDA and ID, who received therapy with a combination medicine of bivalent iron and folic acid in a pharmaceutical form with layer-by-layer release of active substances, was carried out. The follow-up period was 2 months. The study included 28 women of reproductive age. The patients consulted a physician with complaints of deterioration and weakness, feelings of heart rhythm disorders. Various types of arrhythmias were registered in 22 of them after consultation with a cardiologist. IDA and ID were identified in all cases. The complete blood count indicators, serum iron level and ferritin level were investigated before starting the therapy, after 1 and 2 months from the treatment beginning, and the symptoms and complaints of patients were assessed in the monitoring process. Results. There has been a significant subjective improvement, the complete blood count indicators have been restored, the iron repository has been replenished and subjective complaints have been relieved as a result of the combination medicine of iron and folic acid use. There was a good tolerability of the drug, which has resulted in a high adherence to treatment. No patient has stopped taking the medication. Conclusion. The study results demonstrate the effectiveness of treatment with the preparation of bivalent iron and folic acid in the pharmaceutical form with layer-by-layer release of active substances with regard to laboratory parameters, clinical manifestations of iron deficiency anaemia and adherence to treatment.